Results 21 to 30 of about 50,234 (263)
Regulatory Mechanisms in Biosystems, 2019 The activity of antioxidant protection enzymes in the blood serum and colon mucosa in rats was studied under the conditions of 28-days administration of omeprazole on its own and omeprazole together with multiprobiotics "Symbiter" and "Apibact ...
S. V. Pylypenko, A. A. Koval
doaj +1 more source
Journal of Veterinary Internal Medicine, 2023 Background Rebound gastric hyperacidity (RGH) secondary to hypergastrinemia has been suggested to contribute to the rapid recurrence of equine squamous gastric disease (ESGD) in horses after discontinuation of omeprazole.
Bethanie Clark +6 more
doaj +1 more source
Thorax, 2019 Background Cough is a common, disabling symptom of idiopathic pulmonary fibrosis (IPF), which may be exacerbated by acid reflux. Inhibiting gastric acid secretion could potentially reduce cough.
Prosenjit Dutta +12 more
semanticscholar +1 more source
An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer. [PDF]
Clin Pharmacol TherA clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered ...
Piscitelli J +6 more
europepmc +2 more sources
Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. [PDF]
PLoS ONE, 2013 The effect of omeprazole on the mitochondrial carnitine/acylcarnitine transporter has been studied in proteoliposomes. Externally added omeprazole inhibited the carnitine/carnitine antiport catalysed by the transporter.
Annamaria Tonazzi +2 more
doaj +1 more source
Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats
Pharmaceutical Biology, 2019 Context: Omeprazole and astragaloside IV (AS-IV) are widely used for the treatment of gastric ulcers in China clinics. Objective: This study investigates the effects of AS-IV on the pharmacokinetics of omeprazole in rats.
Wei Liu, Guozhi Liu, Jing Liu
doaj +1 more source
Expert Opinion on Drug Metabolism & Toxicology, 2018 Background: Since the first oral glucagon-like peptide-1 analog comprises semaglutide co-formulated with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which induces a transient, localized increase in gastric pH, we have ...
T. Bækdal +3 more
semanticscholar +1 more source
Journal of Korean medical science, 2017 The aim of this study was to examine the effects of CYP2C19*2 and *3 genetic polymorphisms on omeprazole pharmacokinetic (PK) and pharmacodynamic (PD) responses.
Sunny Park +14 more
semanticscholar +1 more source
Binding of omeprazole to protein targets identified by monoclonal antibodies.
PLoS ONE, 2020 Omeprazole is the most commonly used proton pump inhibitor (PPI), a class of medications whose therapeutic mechanism of action involves formation of a disulfide linkage to cysteine residues in the H+/K+ ATPase pump on gastric secretory cells.
Naw May Pearl Cartee, Michael M Wang
doaj +2 more sources
Frontiers in PharmacologyGrapes have been widely used for dietary ailments due to their attributed pharmacological activities. Resveratrol, the chief constituent of grapes, is responsible for their pharmacological benefits.
Tayyaba Iftikhar +12 more
doaj +1 more source